NIH and industry have spent the past year discussing collaborative target validation, but the rubber will meet the road in the next 12 months as pilot projects must be developed if aspirations for a precompetitive consortium are to bear fruit.

NIH Director Francis Collins has publically highlighted target validation as an area where the agency can work with industry to improve drug development efficiency.